lantus and glp 1 Mechanisms by which GLP-1 agonists may exert beneficial effects on the Schematic pathway showing release of

The WSJ piece touches on many Sinclair longevity firms including Sirtris, CohBar, OvaScience, Life Biosciences, and Tally Health

Taken together, the findings suggest oral GLP-1s could: unlock entirely new audiences who previously rejected injections increase treatment uptake among younger adults improve long-term adherence through familiarity and convenience create a substantial switching market among existing GLP-1 users The pill could be the key Oral GLP-1s could completely change the weight loss market in the UK

And also keep in mind that GLP-1s may cause temporary blurry vision due to fluid shifts we see as glucose levels decrease

No adverse effects were reported, confirming the compounds good tolerability